Intellia Therapeutics - investor relations

Skip to main navigation

invest in
partner in
join
- our dna
- we’re in
- i’m in
- join in
- benefits
info
CRISPR/CAS9
pipeline
get in touch
news & resources

stock information

Copyright West LLC. Minimum 15 minutes delayed.

press releases

–

Oct 18, 2018

Summary Toggle Intellia Therapeutics Presents New Data in In Vivo and Ex Vivo Programs at the 26th Annual Congress of the European Society of Gene and Cell Therapy

events and presentation

There are currently no events to display.

corporate governance

corporate governance

financial information

financial information

stock<br />
information

stock
information

investor<br />
FAQs

investor
FAQs

information<br />
request

information
request

IR<br />
contacts

IR & PR
contacts

analyst coverage

invest in

Investor Relations

investor relations
press releases
events & presentations
corporate governance
financial information
stock information
analyst coverage
investor FAQs
information request
IR & PR contacts

partner in

partnering
our partners
who to contact

join

we’re in
i’m in
join in

CRISPR/Cas9

transforming technology
how CRISPR/Cas9 works
strategy
types of edits
delivery of CRISPR/Cas9
engineered cell therapy

pipeline

info

overview
leadership
scientific advisors

get in touch

© Intellia Therapeutics 2018

terms of use

Menu